Donation

Understanding DARZALEX® and DARZALEX FASPRO™

Darzalex® (daratumumab) is the first FDA-approved monoclonal antibody that targets the CD38 protein on the surface of myeloma cells. The original formulation of Darzalex is administered as an intravenous infusion, and the FDA has also approved Darzalex Faspro™ (daratumumab + hyaluronidase-fihj) as a subcutaneous injection. Both formulations are available as monotherapy and as part of combination therapies. 

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.